Liraglutide Injection
Product Images NDC 50090-7501

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 34 technical images submitted to the FDA as part of the official labeling for Liraglutide (NDC 50090-7501). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

→ Figure-1 (figure 1)

→ Figure-2 (figure 2)

→ Figure_3 (figure 3)

→ Figure_4 (figure 4)

→ Figure-5 (figure 5)

→ Pen_image (image 01)

→ Injection-pen (image 22)

→ Needle-example (image 23)

→ Triangle_1 (image 24)

→ Triangle_2 (image 25)

→ Triangle_3 (image 26)

→ Tirangle_4 (image 27)

→ Triangle_5 (image 28)

→ Triangle_6 (image 29)

→ Tirangle_7 (image 30)

→ Triangle_8 (image 31)

→ Image-a (image 32)

→ Image-b (image 33)

→ Image-c (image 34)

→ Image-d (image 35)

→ Image-e (image 36)

→ Image-f (image 37)

→ Image-g (image 38)

→ Image-h (image 39)

→ Image-i (image 40)

→ Image-j (image 41)

→ Image-k (image 42)

→ Image-l (image 43)

→ Image-m (image 44)

→ Image-n (image 45)

→ Image-o (image 46)

→ Image-p (image 47)

→ Image-q (image 48)

→ Label Image (lbl500907501)

FDA Label Image

Figure-1 (Figure 1)

FDA Label Image

Figure-2 (Figure 2)

This text appears to contain data related to a study or experiment comparing the effects of Liraglutide and Placebo on plasma glucose levels, measured in milligrams per deciliter (mg/dL). The units for ISR (pmol/kg/min) are also included. The data points seem to range from 80 to 220, with specific values listed for different scenarios or time points.*

FDA Label Image

Figure_3 (Figure 3)

This is a comparison chart displaying the effects of Glimepiride and Liraglutide in two different doses over a time frame of 40 weeks. The doses specified are 1.2 mg and 1.8 mg of Liraglutide. The chart visually represents the data with values at specific time points and includes the abbreviation LOCF, possibly indicating a method of handling missing data.*

FDA Label Image

Figure_4 (Figure 4)

This is a graph showing the Mean HbA (%) levels over time in weeks for different treatments, including Liraglutide 1.2 mg, Liraglutide 1.8 mg, and Sitagliptin 100 mg. The graph displays how the HbA levels change over a period of 26 weeks.*

FDA Label Image

Figure-5 (Figure 5)

FDA Label Image

Pen_image (Image 01)

This text refers to "Liraglutide injection". Liraglutide is a medication that is injected to help improve blood sugar control in adults with type 2 diabetes. It is also used for weight management in individuals who are overweight or obese. The injection is typically given once a day and works by increasing insulin production in response to food intake, reducing appetite, and slowing down the emptying of the stomach. It is important to follow your healthcare provider's instructions when using Liraglutide injection.*

FDA Label Image

Injection-pen (Image 22)

This description is not available.*

FDA Label Image

Needle-example (Image 23)

This text seems to be a list of components related to a needle. It mentions outer and inner parts like protective cap, needle tab. These components are likely associated with a medical or laboratory setting where needles are used.*

FDA Label Image